ESMO Clinical Practice Guidelines: Haematological Malignancies

The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine.

Latest enhanced and revised set of guidelines

ESMO has Clinical Practice Guidelines on the following Haematological Malignancies: Chronic myeloid leukaemia, Newly diagnosed and relapsed mantle cell lymphoma, Multiple myeloma, Newly diagnosed and relapsed follicular lymphoma, Extranodal diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, Acute lymphoblastic leukaemia, Peripheral T-cell lymphomas, Diffuse large B cell lymphoma, Chronic lymphocytic leukaemia, Hairy cell leukaemia, Philadelphia chromosome-negative chronic myeloproliferative neoplasms, Myelodysplastic syndromes, Hodgkin's lymphoma, Primary cutaneous lymphoma, Acute myeloblastic leukaemia in adult patients, Waldenstrom's macroglobulinaemia, Gastric marginal zone lymphoma of MALT type.
They include information on incidence, diagnosis, staging and risk assessment, treatment, response evaluation and follow-up.